Disease · MONDO_0007187
nevoid basal cell carcinoma syndrome
6 sourcesdiseases-2026-09-18-0.1.0
Download JSON
Cite this record
ConductScience Library. nevoid basal cell carcinoma syndrome. Diseases, record MONDO_0007187. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0007187
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
- Gorlin syndrome, Gorlin-Goltz syndrome, NBCCS, basal cell nevus syndrome, multiple basal cell carcinomas, nevoid basal cell cancer syndrome
- Open Targets
Drugs7
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| PATIDEGIB | CHEMBL538867 | Small molecule | Phase 3 | ClinicalTrials.gov | 4 | 3 | 3 | Drugs and targets |
| VISMODEGIB | CHEMBL473417 | Small molecule | Phase 2 | ClinicalTrials.gov | 4 | 4 | 4 | Drugs and targets |
| SONIDEGIB | CHEMBL2105737 | Small molecule | Phase 2 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| NIVOLUMAB | CHEMBL2108738 | Antibody | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| TAZAROTENE | CHEMBL1657 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| GUSACITINIB | CHEMBL4594275 | Small molecule | Phase 1/2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| BMS-833923 | CHEMBL3545403 | Small molecule | Unknown | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
Targets10
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| SMO | Protein smoothened | 4 | Smoothened homolog antagonist; Smoothened homolog inhibitor | Phase 3 | https://conductscience.org/library/genes/6608 | Drugs and targets |
| JAK1 | Janus Kinase (JAK) | 1 | Janus Kinase (JAK) inhibitor | Phase 1/2 | https://conductscience.org/library/genes/3716 | Drugs and targets |
| JAK2 | Janus Kinase (JAK) | 1 | Janus Kinase (JAK) inhibitor | Phase 1/2 | https://conductscience.org/library/genes/3717 | Drugs and targets |
| JAK3 | Janus Kinase (JAK) | 1 | Janus Kinase (JAK) inhibitor | Phase 1/2 | https://conductscience.org/library/genes/3718 | Drugs and targets |
| PDCD1 | Programmed cell death protein 1 | 1 | Programmed cell death protein 1 inhibitor | Phase 2 | https://conductscience.org/library/genes/5133 | Drugs and targets |
| RARA | Retinoic acid receptor | 1 | Retinoic acid receptor agonist | Phase 2 | https://conductscience.org/library/genes/5914 | Drugs and targets |
| RARB | Retinoic acid receptor | 1 | Retinoic acid receptor agonist | Phase 2 | https://conductscience.org/library/genes/5915 | Drugs and targets |
| RARG | Retinoic acid receptor | 1 | Retinoic acid receptor agonist | Phase 2 | https://conductscience.org/library/genes/5916 | Drugs and targets |
| SYK | Tyrosine-protein kinase SYK | 1 | Tyrosine-protein kinase SYK inhibitor | Phase 1/2 | https://conductscience.org/library/genes/6850 | Drugs and targets |
| TYK2 | Janus Kinase (JAK) | 1 | Janus Kinase (JAK) inhibitor | Phase 1/2 | https://conductscience.org/library/genes/7297 | Drugs and targets |
Trials12
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01815840 | A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas | Phase 2 | 229 | 2016-08-04 | Basal Cell Carcinoma | VISMODEGIB | Its record names the disease | ClinicalTrials.gov |
| NCT03703310 | Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas (BCCs) in Subjects With Basal Cell Nevus Syndrome (Gorlin Syndrome) | Phase 3 | 174 | 2024-07-03 | Basal Cell Nevus Syndrome | PATIDEGIB | Its record names the disease | ClinicalTrials.gov |
| NCT04308395 | Extension Study of Patidegib Topical Gel, 2% in Subjects With Gorlin Syndrome (Basal Cell Nevus Syndrome) | Phase 3 | 108 | 2024-09-24 | Basal Cell Nevus Syndrome | PATIDEGIB | Its record names the disease | ClinicalTrials.gov |
| NCT00957229 | To Determine The Efficacy and Safety of GDC-0449 in Patients With Basal Cell Nevus Syndrome (BCNS) | Phase 2 | 41 | 2021-01-11 | Basal Cell Nevus Syndrome, Gorlin Syndrome | VISMODEGIB | Its record names the disease | ClinicalTrials.gov |
| NCT00489086 | Topical Tazarotene in Treating Patients With Basal Cell Skin Cancer and Basal Cell Nevus Syndrome on the Face | Phase 2 | 36 | 2016-02-11 | Neoplastic Syndrome | TAZAROTENE | Its record names the disease | ClinicalTrials.gov |
| NCT00961896 | A Trial to Evaluate the Safety, Local Tolerability, Pharmacokinetics and Pharmacodynamics of LDE225 on Skin Basal Cell Carcinomas in Gorlin Syndrome Patients | Phase 2 | 18 | 2015-09-21 | Treatment for Basal Cell Carcinomas (BCCs) in Gorlin Syndrome Patients | SONIDEGIB | Its record names the disease | ClinicalTrials.gov |
| NCT02762084 | Trial of Patidegib Gel 2%, 4%, and Vehicle to Decrease the Number of Surgically Eligible Basal Cell Carcinomas in Gorlin Syndrome Patients | Phase 2 | 17 | 2019-07-15 | Basal Cell Nevus Syndrome | PATIDEGIB | Its record names the disease | ClinicalTrials.gov |
| NCT01350115 | Efficacy, Safety and Pharmacokinetics of Oral LDE225 in Treatment of Patients With Nevoid Basal Cell Carcinoma Syndrome (NBCCS) | Phase 2 | 10 | 2015-10-19 | Basal Cell Carcinoma, Gorlin Syndrome, Nevoid Basal Cell Carcinoma Syndrome | SONIDEGIB | Its record names the disease | ClinicalTrials.gov |
| NCT05463757 | Oral Hedgehog Inhibitors in the Treatment of Basal Cell Carcinoma in the Netherlands: a Prospective Registration Study | 80 | Basal Cell Carcinoma, Locally Advanced Basal Cell Carcinoma, Metastatic Basal Cell Carcinoma, Gorlin Syndrome, Basal Cell Nevus Syndrome, Carcinoma, Basal Cell, Carcinoma, Basal Cell Tumor, Skin Cancer, Neoplasm of Skin, Neoplasms, Basal Cell | SONIDEGIB, VISMODEGIB | Its record names the disease | ClinicalTrials.gov | ||
| NCT03208296 | Study of ASN-002 to Treat Basal Cell Carcinomas (BCCs) in Individuals With Basal Cell Nevus Syndrome (BCNS) | Phase 1/2 | 24 | Basal Cell Carcinoma in Basal Cell Nevus Syndrome | GUSACITINIB | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 12
See all 12 trialsComparisons in its trials8
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Vismodegib Intermittent Schedule vs Vismodegib Induction Followed by Intermittent Schedule: serious adverse events | 24 of 114 | 23 of 113 | 227 | NCT01815840 | Trial comparisons |
| Patidegib Topical Gel, 2%, vs Patidegib Topical Gel, Vehicle: deaths from any cause | 0 of 87 | 0 of 87 | 174 | NCT03703310 | Trial comparisons |
| Patidegib Topical Gel, 2%, vs Patidegib Topical Gel, Vehicle: serious adverse events | 5 of 87 | 7 of 87 | 174 | NCT03703310 | Trial comparisons |
| Patidegib Topical Gel, 2%, vs Patidegib Topical Gel, Vehicle: Percentage of Participants Developing >=2 Facial New BCCs | 45 of 83 | 55 of 86 | 169 | NCT03703310 | Trial comparisons |
| Patidegib Topical Gel, 2%, vs Patidegib Topical Gel, Vehicle: Percentage of Participants Developing >=1 Facial New BCCs | 56 of 83 | 65 of 86 | 169 | NCT03703310 | Trial comparisons |
| Sugar Pill vs GDC-0449: deaths from any cause | 0 of 15 | 2 of 40 | 55 | NCT00957229 | Trial comparisons |
| Sugar Pill vs GDC-0449: serious adverse events | 2 of 15 | 21 of 40 | 55 | NCT00957229 | Trial comparisons |
| Patidegib Gel vs Vehicle Gel: The Number of Participants Reporting New SEBs on the Face From Baseline for the Combined Patidegib Treatment Groups | 2 of 12 | 3 of 5 | 17 | NCT02762084 | Trial comparisons |
Papers from its trials6
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0007187
GET https://conductscience.org/api/diseases/v1/MONDO_0007187/drugs